Lotan Y - Search Results

1

Recent advances in the metabolomic study of bladder cancer.

Amara CS, Vantaku V, Lotan Y, Putluri N. Amara CS, et al. Among authors: lotan y. Expert Rev Proteomics. 2019 Apr;16(4):315-324. doi: 10.1080/14789450.2019.1583105. Epub 2019 Feb 26. Expert Rev Proteomics. 2019. PMID: 30773067 Free PMC article. Review.

2

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.

Lotan Y, Roehrborn CG. Lotan Y, et al. Urology. 2003 Jan;61(1):109-18; discussion 118. doi: 10.1016/s0090-4295(02)02136-2. Urology. 2003. PMID: 12559279 Review.

3

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Svatek RS, et al. Among authors: lotan y. Cancer. 2006 Apr 15;106(8):1701-7. doi: 10.1002/cncr.21795. Cancer. 2006. PMID: 16541433 Free article.

4

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Among authors: lotan y. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

5

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Lotan Y, Svatek RS, Sagalowsky AI. Lotan Y, et al. Cancer. 2006 Sep 1;107(5):982-90. doi: 10.1002/cncr.22084. Cancer. 2006. PMID: 16862567 Free article.

6

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Karam JA, et al. Among authors: lotan y. Lancet Oncol. 2007 Feb;8(2):128-36. doi: 10.1016/S1470-2045(07)70002-5. Lancet Oncol. 2007. PMID: 17267327

7

Nomograms for bladder cancer.

Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Shariat SF, et al. Among authors: lotan y. Eur Urol. 2008 Jul;54(1):41-53. doi: 10.1016/j.eururo.2008.01.004. Epub 2008 Jan 15. Eur Urol. 2008. PMID: 18207314 Review.

8

Screening for bladder cancer using urine-based tumor markers.

Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF. Svatek RS, et al. Among authors: lotan y. Minerva Urol Nefrol. 2008 Dec;60(4):247-53. Minerva Urol Nefrol. 2008. PMID: 18923361 Review.

9

Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.

Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y. Youssef RF, et al. Among authors: lotan y. Urol Oncol. 2012 May-Jun;30(3):273-7. doi: 10.1016/j.urolonc.2010.02.012. Epub 2010 May 6. Urol Oncol. 2012. PMID: 20451422

10

Cost-effectiveness of bladder cancer screening.

Lotan Y, Svatek RS. Lotan Y, et al. Expert Rev Pharmacoecon Outcomes Res. 2007 Dec;7(6):627-32. doi: 10.1586/14737167.7.6.627. Expert Rev Pharmacoecon Outcomes Res. 2007. PMID: 20528324

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

768 results

Search Page

Filters